{"id":"W2099670937","doi":"10.1111/dom.12494","title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial ( <scp>EASE</scp> ‐1)","year":2015,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Management and Research","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Eli Lilly and Company; Boehringer Ingelheim","keywords":"Empagliflozin; Placebo; Medicine; Insulin; Type 2 diabetes; Clinical endpoint; Internal medicine; Diabetes mellitus; Randomized controlled trial; Adverse effect; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001483549,0.001441956,0.003304479,0.0004545379,0.0003423714,0.000965547,0.0008315409,0.001769151,0.006337528],"category_scores_gemma":[0.001379188,0.0006630977,0.001593804,0.0004625052,0.0008910763,0.0008270228,0.0003610933,0.002550873,0.0007469783],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004999978,"about_ca_system_score_gemma":0.0009130783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007396963,"about_ca_topic_score_gemma":0.001710023,"domain_scores_codex":[0.999485,0.0002459972,0.00004473401,0.0001083694,0.00004801388,0.00006790966],"domain_scores_gemma":[0.9993423,0.0001829924,0.000189638,0.00005015413,0.00004277087,0.0001921964],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9827417,0.004129183,0.0003592005,0.0004885594,0.0005566332,0.0000196861,0.0000156899,0.0001264246,0.001604284,0.00002301009,0.0002709583,0.009664709],"study_design_scores_gemma":[0.9714115,0.02686447,0.001066212,0.00001718727,0.0002016279,0.00001219261,0.000004483722,0.0001260097,0.0001438682,0.00001476229,0.0001328519,0.000004968692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872583,0.005940951,0.0005550554,0.0005476896,0.0006918894,0.002917792,0.0006684768,0.0001268971,0.001293119],"genre_scores_gemma":[0.9819629,0.00508596,0.001951415,0.001265346,0.001062663,0.004869548,0.001066671,0.00002076654,0.002714547],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006337528,"threshold_uncertainty_score":0.02120113,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01363860986802511,"score_gpt":0.2461924121162025,"score_spread":0.2325538022481774,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}